Endocrine Abstracts

Ropeginterferon alfa-2b is a mono-pegylated type I interferon (P-I) used in myeloproliferative neoplasm (MPN). Thyroid dysfunction (TD) is a well recognised side-effect of P-I (1). We conducted a review determining TD prevalence and current practice on thyroid function (TF)/antibody (TAB) monitoring during P-I treatment. Retrospective data was collected, from electronic and physical medical records from July 2019-March 2024, on 37 adult MPN patients in the South-West of Irelan...

Introduction: Pheochromocytomas are rare catecholamine-secreting tumors, primarily arising from the adrenal medulla, typically presenting with hypertension, palpitations, and headaches. Diagnosis involves hormonal evaluation and CT imaging with a washout of <40-60%. Recent studies show exceptions, with some tumours mimicking non-functional adenomas, displaying >60% washout. We present a case exemplifying this, where a symptomatic patient had normal initial biochemical ...

Diabetes Mellitus is one of the leading causes of morbidity and healthcare costs internationally. Innovations in treatment options however, including insulin analogues, continue to emerge. While insulin therapy may be required for certain patients with Type 2 Diabetes Mellitus (T2DM), it bestows upon them the opportunity for potential harm, namely insulin overdoses, whether accidental or intentional. This case details an intentional ultra-long-acting insulin analogue overdose ...

FPLD is a rare monogenic cause of insulin resistance. We document responses to treatment with metformin in 2 adolescent sisters with FPLD due to heterozygosity for R482W LMNA gene mutation.The probands, aged 14 and 16 years, presented with secondary amenorrhoea, hirsutism and progressive acanthosis nigricans. Phenotypically they showed central obesity, nuchal enlargement, and thin muscular arms. These changes occurred post-pubertally. Anthrpometri...

A 74 year old lady was admitted with an agitated depression. She had been taking Lorazepam and Olanzapine throughout the preceding 6 months. Escitalopram had been introduced 2 months prior to admission and the dose was escalated 3 weeks prior to presentation. The dose of Olanzapine was doubled at the same time.She was treated with sotalol for atrial fibrillation and she had documented labile hypertension (BP range 77/57–250/118). She had fluctuating...